Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

P Nair, M Gaga, E Zervas, K Alagha, F E Hargreave, P M O'Byrne, P Stryszak, L Gann, J Sadeh, P Chanez, Study Investigators, Liam Heaney

Research output: Contribution to journalArticlepeer-review

237 Citations (Scopus)

Abstract

Increased numbers of neutrophils are reported in the airways of patients with severe asthma. It is not clear if they contribute to the lack of control and severity. There are currently no strategies to investigate this by decreasing neutrophil numbers in the airways.
Original languageEnglish
Pages (from-to)1097-103
Number of pages7
JournalClinical & Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
Volume42
Issue number7
DOIs
Publication statusPublished - Jul 2012

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial'. Together they form a unique fingerprint.

Cite this